San Diego-based BioAtla, a company that produces cancer therapies, wrapped its initial public offering.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $3.68 |
|---|---|
| 52-week range | $2.01 - $12.15 |
| 50-day moving average | $7.90 |
| 200-day moving average | $5.97 |
| Wall St. target price | $26.14 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.85 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.68 from 2023-01-26
| 1 week (2023-01-20) | 5.75% |
|---|---|
| 1 month (2022-12-27) | -52.82% |
| 3 months (2022-10-27) | -44.33% |
| 6 months (2022-07-27) | -0.81% |
| 1 year (2022-01-27) | -58.32% |
|---|---|
| 2 years (2021-01-27) | -91.63% |
| 3 years (2020-01-23) | N/A |
| 5 years (2018-01-23) | N/A |
| Gross profit TTM | $-58,024,000 |
|---|---|
| Return on assets TTM | -27.61% |
| Return on equity TTM | -54.83% |
| Profit margin | 0% |
| Book value | $3.80 |
| Market capitalisation | $182.7 million |
TTM: trailing 12 months
We're not expecting Bioatla Inc to pay a dividend over the next 12 months.
Over the last 12 months, Bioatla Inc's shares have ranged in value from as little as $2.01 up to $12.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bioatla Inc's is 0.633. This would suggest that Bioatla Inc's shares are less volatile than average (for this exchange).
To put Bioatla Inc's beta into context you can compare it against those of similar companies.
BioAtla, Inc. , a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
